Cargando…

CDK9 inhibitors in acute myeloid leukemia

Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boffo, Silvia, Damato, Angela, Alfano, Luigi, Giordano, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824552/ https://www.ncbi.nlm.nih.gov/pubmed/29471852 http://dx.doi.org/10.1186/s13046-018-0704-8

Ejemplares similares

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia
por: Anshabo, Abel Tesfaye, et al.
Publicado: (2022)

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
por: Sorf, Ales, et al.
Publicado: (2020)

HDAC Inhibitors in Acute Myeloid Leukemia
por: San José-Enériz, Edurne, et al.
Publicado: (2019)

Checkpoint Inhibitors in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2023)

Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
por: Gaur, Tarang, et al.
Publicado: (2023)

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
por: Liu, Wei, et al.
Publicado: (2021)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia
por: Luedtke, Daniel A., et al.
Publicado: (2020)

Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia
por: Labbozzetta, Manuela, et al.
Publicado: (2023)

DPP8/9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia
por: Johnson, Darren C., et al.
Publicado: (2018)

Clinical use of FLT3 inhibitors in acute myeloid leukemia
por: Sutamtewagul, Grerk, et al.
Publicado: (2018)

FLT3 inhibitors: clinical potential in acute myeloid leukemia
por: Hospital, Marie-Anne, et al.
Publicado: (2017)

Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
por: Takahashi, Shinichiro
Publicado: (2023)

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
por: Lopez, Sophie, et al.
Publicado: (2016)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
por: Eguchi, Motoki, et al.
Publicado: (2020)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
por: Song, Moo-Kon, et al.
Publicado: (2022)

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
por: Porazzi, Patrizia, et al.
Publicado: (2021)

Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia
por: Lambert, Mélanie, et al.
Publicado: (2019)

Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
por: Li, Linzhang, et al.
Publicado: (2022)

Acute Myeloid Leukemia: Is It T Time?
por: Khoud, Meriem Ben, et al.
Publicado: (2021)

New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics
por: Porcù, Elena, et al.
Publicado: (2021)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Harnessing Immune Response in Acute Myeloid Leukemia
por: Riva, Carola, et al.
Publicado: (2023)

CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism
por: Huang, Wen-Li, et al.
Publicado: (2021)

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
por: He, Lixiazi, et al.
Publicado: (2022)

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
por: Gurska, Lindsay, et al.
Publicado: (2023)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

Retracted: Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
por: Healthcare Engineering, Journal of
Publicado: (2023)

Classification of acute myeloid leukemia
por: Hwang, Sang Mee
Publicado: (2020)

CDK9 inhibitors in multiple myeloma: a review of progress and perspectives
por: Borowczak, Jędrzej, et al.
Publicado: (2022)

Oral Manifestations and Complications in Childhood Acute Myeloid Leukemia
por: Cammarata-Scalisi, Francisco, et al.
Publicado: (2020)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

Novel Agents for Acute Myeloid Leukemia
por: Luppi, Mario, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1t8n3ufa7fifprfpdfgpd1t0hu